On the other hand, for patients with core-binding-factor AML, i.e., AML with t(8;21); AML with inv(16) or t(16;16); and an NPM1 mutation in absence of an FLT3 mutation or with FLT3 low allelic burden, ELN recommends, after induction, up to four courses of ID/HDARAC, even though it remains unclear whether ID or HDARAC of two or three course would be preferred [15,16]. Here, NPM1 is linked to acute myeloid leukemia.